Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

Sandro Pignata, I. L. Ray-Coquard, Simona Frezzini et al.|The Lancet Oncology|2021

Cited by 148